If you've spent any time on the internet over the last two years, you've heard of tirzepatide — usually under one of its brand names, Mounjaro (for type 2 diabetes) or Zepbound (for obesity). What you may not have heard is why it's getting the attention. It isn't just "another Ozempic." Mechanistically and clinically, it's a different drug, and the trial data has reset what we expect from this class.

This is a plain-English walkthrough of what tirzepatide actually does, what the headline trials showed, how it stacks up against semaglutide head-to-head, what's going on with the microdosing trend, and — the question I get most in clinic — who actually benefits versus who's chasing a number on a scale.

What tirzepatide actually is

Semaglutide, liraglutide, and dulaglutide are GLP-1 receptor agonists. They mimic glucagon-like peptide-1, a gut hormone your body releases after meals. The receptor they hit slows gastric emptying, increases insulin secretion when blood sugar is high, and dampens appetite.

Tirzepatide does the same thing — but it also activates a second receptor called GIP (glucose-dependent insulinotropic polypeptide). That's why you'll see it called a "twincretin" or a "dual agonist." Hitting GIP in addition to GLP-1 appears to amplify the glucose-lowering and appetite effects, and may also push more energy through fat oxidation rather than just appetite suppression. Whether that mechanistic story fully explains the clinical advantage is still debated, but the clinical advantage itself is well-documented.

The diabetes trials: SURPASS

Tirzepatide's diabetes program is called SURPASS. The most clinically interesting one for our purposes is SURPASS-2, a head-to-head against semaglutide 1 mg in adults with type 2 diabetes. Over 40 weeks, tirzepatide produced larger drops in A1c (roughly 2.0–2.3% versus semaglutide's 1.9%) and substantially more weight loss (about 16–25 lbs depending on dose, versus around 13 lbs for semaglutide).

SURPASS-3 and SURPASS-4 compared tirzepatide to insulin (degludec and glargine respectively). In both, tirzepatide outperformed on A1c and patients lost weight rather than gaining it — the usual price of insulin therapy.

SURPASS-CVOT, the cardiovascular outcomes trial, compared tirzepatide to dulaglutide in T2D patients with established cardiovascular disease. It met its non-inferiority endpoint, confirming that tirzepatide is at least as cardioprotective as a GLP-1 already known to reduce cardiovascular events.

The obesity trials: SURMOUNT

SURMOUNT is the program that put tirzepatide on the front page.

SURMOUNT-1 (published in NEJM, 2022) enrolled adults with obesity but without diabetes. After 72 weeks, mean weight loss was:

To put that in perspective: roughly half of the 15 mg group lost more than 20% of their body weight. About a third lost more than a quarter. Numbers like that had previously been the territory of bariatric surgery, not an injection.

SURMOUNT-2 ran the same protocol in patients who had both obesity and type 2 diabetes. Weight loss was somewhat smaller (around 13–15%), which is the usual story — diabetes blunts pharmacologic weight loss — but still well beyond what we'd previously seen in this population.

SURMOUNT-3 looked at patients who first did 12 weeks of intensive lifestyle intervention and then either started tirzepatide or placebo. The tirzepatide group lost an additional ~18% on top of their lifestyle losses; the placebo group regained.

SURMOUNT-4 was the withdrawal trial. Patients who lost weight on open-label tirzepatide were randomized to either continue or switch to placebo. The continuing group kept losing. The placebo group regained roughly half their loss within a year. This is the trial people quote when they tell you "you'll just gain it back if you stop" — and they're not wrong, though we should also be honest that this is true of essentially every chronic-disease medication: stop the lipid drug, the LDL comes back; stop the antihypertensive, the BP comes back.

Tirzepatide vs. semaglutide, head-to-head

For a long time we only had cross-trial comparisons — and cross-trial comparisons are notoriously unreliable. SURMOUNT-5 changed that. It directly compared tirzepatide (max tolerated dose, 10 or 15 mg) to semaglutide 2.4 mg (the Wegovy dose) in adults with obesity and without diabetes, over 72 weeks.

Mean weight loss: tirzepatide 20.2% vs. semaglutide 13.7%. The gap held across subgroups.

That ~6.5 percentage-point difference is the largest direct comparison we have between two drugs in this class, and it's the trial I cite when patients ask which one to use if cost and tolerance aren't the deciding factor. Semaglutide is still excellent — 13.7% mean loss is a serious clinical outcome — but on average, tirzepatide wins.

Beyond weight: what else tirzepatide is doing

If tirzepatide were only about the scale, it would still be useful. It's not only about the scale.

Sleep apnea

SURMOUNT-OSA (NEJM, 2024) showed roughly 25–30 fewer apnea-hypopnea events per hour in patients with obesity and moderate-to-severe OSA. That's not a marginal effect — many participants moved from "severe" to "mild" OSA, and a meaningful subset reached criteria for resolution. The FDA approved tirzepatide for moderate-to-severe OSA with obesity on the strength of this trial.

Heart failure with preserved ejection fraction

The SUMMIT trial (NEJM, 2024) tested tirzepatide in patients with HFpEF and obesity. It improved exercise capacity, quality-of-life scores, and reduced cardiovascular events. HFpEF has historically been one of the hardest cardiology problems to move; this is a meaningful result.

Liver fat (MASH/NAFLD)

In sub-studies and the SYNERGY-NASH trial, tirzepatide produced large reductions in liver fat content and rates of histologic resolution of MASH (formerly called NASH). This is consistent with what we'd expect from any drug that drops 15–20% of body weight, but the effect size is impressive.

Lipids and blood pressure

Across trials, triglycerides typically drop 20–25%, blood pressure falls 5–7 mmHg systolic, and HDL nudges up modestly. These are downstream effects of weight loss and improved insulin sensitivity, but they compound the cardiovascular benefit.

Microdosing: what it is, and what the evidence does and doesn't say

"Microdosing" tirzepatide has become a fashionable term in the longevity and biohacker corners of the internet, and increasingly in clinical practice. It usually means using sub-therapeutic doses — often 0.5 to 2.5 mg per week — instead of titrating up to the standard 5–15 mg used in the trials.

The reasons people pursue it are reasonable:

Now the honest part. There is no published randomized trial of microdosing tirzepatide. Every weight-loss number you've read came from doses of 5 mg and up. Sub-therapeutic dosing data exists only as the early titration arms of larger trials, where patients spent four weeks each at 2.5 mg, 5 mg, etc. before reaching their target dose. We have anecdote, clinical experience, and titration-phase data — we don't have hard endpoints from a microdosing arm.

That doesn't mean microdosing is bunk. It means the honest answer to "how much weight will I lose on 1 mg weekly?" is "less than the trials, by an unknown amount, with much better tolerance." For some patients — especially maintenance and metabolically near-normal patients — that's the right tradeoff. For someone with a BMI of 38 chasing meaningful weight loss, microdosing is probably under-treating.

How tirzepatide compares to the rest of the class

Quick relative ranking, using head-to-head trials where they exist and cross-trial comparisons where they don't:

Who actually benefits

The obvious indications

If your BMI is ≥30, or ≥27 with a weight-related comorbidity (T2D, hypertension, dyslipidemia, obstructive sleep apnea, MASLD), you fall inside the FDA-approved label for Zepbound. The case for treatment is strong, and the trial data is most directly applicable to you.

Type 2 diabetes patients not at A1c goal on metformin alone are similarly straightforward — particularly if there's also an obesity component. Mounjaro is the right tool.

The less obvious cases

The patients I see most often in clinic don't quite fit those neat boxes:

Who should pump the brakes

The bottom line

Tirzepatide is the most effective single agent we have for weight loss, and it's quietly one of the more interesting cardiometabolic drugs of the last decade. Its benefits in sleep apnea, heart failure with preserved ejection fraction, and liver disease are not afterthoughts — they're some of the most promising secondary findings in the SURMOUNT and SURPASS programs.

Microdosing is a clinically reasonable approach for tolerability and maintenance and a poor approach for treating significant obesity. The trial evidence sits at standard doses; that's what to expect when patients ask "what kind of results will I see?"

And — as with every drug in this class — the medication is the easy part. The protein, the resistance training, the sleep, and the stress management are what determine whether the weight you lose is the weight you wanted to lose, and whether the body composition underneath the scale number is one you actually want to live in.